NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
Clinical Trials
764 trialsNCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT06005974 2026-02-23
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
Phase 2 Terminated
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT05733611 2026-02-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune Inc.
Phase 2 Terminated
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT05814666 2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2 Terminated
NCT04617054 2026-01-21
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Nuvation Bio Inc.
Phase 2 Terminated
NCT04150029 2026-01-13
STIMULUS-AML1
Novartis
Phase 2 Terminated
NCT05172596 2026-01-13
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Novartis
Phase 2 Terminated
NCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT06478862 2026-01-09
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
Phase 2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04986852 2025-12-30
Olinvacimab With Pembrolizumab in Patients With mTNBC
PharmAbcine
Phase 2 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT05179603 2025-12-24
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
Phase 2 Terminated
NCT06359379 2025-12-18
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Shuttle Pharmaceuticals, Inc.
Phase 2 Terminated
NCT03758417 2025-12-17
CARTIFAN-1
Nanjing Legend Biotech Co.
Phase 2 Terminated
NCT05998447 2025-12-16
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Genome & Company
Phase 2 Terminated
NCT03363763 2025-12-01
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Aucta Pharmaceuticals, Inc
Phase 2 Terminated
NCT06964165 2025-11-26
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Tesaro, Inc.
Phase 2 Terminated
NCT05496569 2025-11-21
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT05954143 2025-11-20
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Bolt Biotherapeutics, Inc.
Phase 2 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT04024436 2025-11-13
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04504916 2025-11-10
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT05798611 2025-11-06
ARTIST
Artios Pharma Ltd
Phase 2 Terminated
NCT03822117 2025-11-04
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Corporation
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT04958785 2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2 Terminated
NCT04511130 2025-10-30
ARTEMIS
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT00726232 2025-10-29
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Incyte Corporation
Phase 2 Terminated
NCT04524689 2025-10-29
CARMEN-LC05
Sanofi
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT05513703 2025-10-24
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 2 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT00422877 2025-10-16
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
American Regent, Inc.
Phase 2 Terminated
NCT04926831 2025-10-16
Geometry-N
Novartis
Phase 2 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT05370521 2025-10-09
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
Spruce Biosciences
Phase 2 Terminated
NCT04189445 2025-10-08
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
Phase 2 Terminated